Acadia Pharmaceuticals Stock Alpha and Beta Analysis
| ACAD Stock | USD 17.50 0.72 4.29% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ACADIA Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in ACADIA Pharmaceuticals over a specified time horizon. Remember, high ACADIA Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ACADIA Pharmaceuticals' market risk premium analysis include:
Beta 0.9 | Alpha 0.17 | Risk 2.83 | Sharpe Ratio 0.0191 | Expected Return 0.0539 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
ACADIA |
ACADIA Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ACADIA Pharmaceuticals market risk premium is the additional return an investor will receive from holding ACADIA Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ACADIA Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ACADIA Pharmaceuticals' performance over market.| α | 0.17 | β | 0.90 |
ACADIA Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of ACADIA Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how ACADIA Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.ACADIA Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how ACADIA Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ACADIA Pharmaceuticals shares will generate the highest return on investment. By understating and applying ACADIA Pharmaceuticals stock market price indicators, traders can identify ACADIA Pharmaceuticals position entry and exit signals to maximize returns.
ACADIA Pharmaceuticals Return and Market Media
The median price of ACADIA Pharmaceuticals for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 18.16 with a coefficient of variation of 5.39. The daily time series for the period is distributed with a sample standard deviation of 0.98, arithmetic mean of 18.14, and mean deviation of 0.84. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 9913 shares by Brendan Teehan of ACADIA Pharmaceuticals subject to Rule 16b-3 | 12/20/2024 |
2 | Disposition of 31747 shares by Davis Stephen of ACADIA Pharmaceuticals at 15.28 subject to Rule 16b-3 | 01/22/2025 |
3 | ACADIA Pharmaceuticals Trying To Close In On Key Technical Measure | 02/06/2025 |
4 | Disposition of 1353 shares by Mark Schneyer of ACADIA Pharmaceuticals subject to Rule 16b-3 | 02/21/2025 |
5 | Disposition of 773 shares by Mark Schneyer of ACADIA Pharmaceuticals at 19.96 subject to Rule 16b-3 | 02/24/2025 |
6 | ACADIA Pharmaceuticals Inc. Receives Consensus Recommendation of Moderate Buy from Analysts | 02/28/2025 |
7 | Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 Phase 1 Study | 03/03/2025 |
8 | Clinical Data from Open-Label DAFFODIL Study Evaluating Long-term Safety of DAYBUE in Patients with Rett Syndrome Published in Med | 03/05/2025 |
9 | Insider Sell Elizabeth Garofalo Sells 4,919 Shares of ACADIA Pharmaceuticals Inc | 03/07/2025 |
10 | Acadia Sets Stage for Strategic Updates at 3 Major CNS Conferences - Key Dates for Investors - StockTitan | 03/13/2025 |
About ACADIA Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ACADIA or other stocks. Alpha measures the amount that position in ACADIA Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 0.8 | 2.61 | 5.05 | 4.8 | Days Of Inventory On Hand | 238.26 | 285.89 | 97.89 | 93.0 |
ACADIA Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of ACADIA Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ACADIA Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ACADIA Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ACADIA Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of ACADIA Pharmaceuticals' management manipulating its earnings.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with ACADIA Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out ACADIA Pharmaceuticals Backtesting, ACADIA Pharmaceuticals Valuation, ACADIA Pharmaceuticals Correlation, ACADIA Pharmaceuticals Hype Analysis, ACADIA Pharmaceuticals Volatility, ACADIA Pharmaceuticals History and analyze ACADIA Pharmaceuticals Performance. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
ACADIA Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.